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Abstract 
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor 
(BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial 
hypertension (PAH). However, selective targeting of this signaling pathway using 
BMP ligands has not yet been explored as a therapeutic strategy. We identified BMP9 
as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in 
both pulmonary arterial endothelial cells and blood outgrowth endothelial cells from 
subjects with PAH bearing mutations in BMPR-II. In vivo, we report the spontaneous 
generation of PAH in a mouse model bearing a heterozygous knock-in of a human 
BMPR-II mutation, R899X. Administration of BMP9 reversed established PAH in 
Bmpr2+/R899X mice, as well as in models of disease developed in response to either 
monocrotaline or VEGF receptor inhibition combined with chronic hypoxia. These 
results demonstrate the promise of direct enhancement of endothelial BMP signaling 
as a novel therapeutic strategy for PAH.  
 3
Heritable and idiopathic pulmonary arterial hypertension (PAH) are characterized by 
narrowing and obliteration of precapillary pulmonary arteries, secondary to 
proliferation and apoptosis resistance of endothelial cells, smooth muscle cells, and 
fibroblasts1. The resulting increase in pulmonary vascular resistance causes severe 
elevation of pulmonary artery pressure, leading to right ventricular hypertrophy and 
ultimately death from right heart failure2. The identification of heterozygous germline 
mutations in the gene encoding the bone morphogenetic protein type II receptor 
(BMPR-II) in 20003,4 provided major insights into the pathobiology of heritable PAH. 
Subsequent studies also identified BMPR-II mutations in 15-40% of idiopathic PAH 
cases5, and found that reduced BMPR-II expression is a feature of non-genetic forms 
of PAH in humans6 and animal models7.  
Genetic evidence strongly implicates the endothelial cell as the key initiating 
cell type in PAH. Previous studies showed that conditional deletion of BMPR-II in 
the endothelium is sufficient to induce PAH in a proportion of mice8 and that rescue 
of endothelial BMPR-II expression reverses experimental pulmonary hypertension9-11. 
In addition, mutations in the type I receptor, ALK-112, and the type I receptor 
accessory protein, endoglin13, are found in individuals with PAH, both of which are 
almost exclusively expressed on the endothelium. Despite this evidence, the precise 
nature of the endothelial dysfunction in the pathobiology of PAH and the involvement 
of BMP signaling in this process remain uncertain. Although established PAH is 
characterized by the excessive clonal proliferation of pulmonary endothelial cells14 as 
a component of obstructive cellular lesions, the initiation of disease pathology15,16,17 
has been linked to a paradoxical increase in endothelial cell apoptosis. Additional 
studies have identified a role for endothelial BMPR-II loss in the exacerbation of 
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vascular permeability and the altered translocation of leukocytes across the vascular 
wall18-20.  
While in vitro studies using pulmonary artery smooth muscle cells (PASMCs) 
demonstrated that increasing concentrations of BMP ligand overcomes the loss of 
function associated with mutations in the BMP signaling pathway21, to date, no study 
has therapeutically delivered BMP ligand in vivo to provide proof-of-concept for such 
an approach in the treatment of PAH. The complexity of the BMP receptor family, 
which is comprised of four type-II receptors, five type-I receptors and over twenty 
BMP ligands22, may account for the absence of such studies. Identifying an 
appropriate ligand to selectively target the pulmonary endothelium presents a 
significant challenge. Recently, BMPR-II was found to form a signaling complex with 
ALK-1 and signal specifically in response to BMP9 and 10 in microvascular 
endothelial cells23. Unlike other BMPs, BMP9 circulates at measureable 
concentrations in serum and is thought to act as a vascular quiescence factor, blocking 
angiogenesis in vitro24 and in vivo25, making it a candidate for therapeutically 
targeting the dysfunctional pulmonary endothelium. 
Here we examined the therapeutic administration of BMP9 to prevent and 
reverse established PAH by selectively enhancing endothelial BMPR-II signaling. 
BMP9 acts directly on the endothelium to promote vascular stability by preventing 
both apoptosis and angiogenesis, and by promoting monolayer integrity. We also 
report a novel mouse model of PAH, bearing a constitutive knock-in of a common 
human disease causing mutation at amino acid 899 (R899X) of the endogenous Bmpr2 
locus. Unlike previous mouse models of somatic BMPR-II haploinsufficiency26,27, 
mice heterozygous for this knock-in (Bmpr2+/R899X) spontaneously develop pulmonary 
hypertension. The therapeutic delivery of BMP9 effectively prevents and reverses 
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established pulmonary hypertension in both the knock-in model and the 
monocrotaline and sugen-hypoxia models of PAH. Together, these studies underscore 
a role for BMP9 as a vascular stability and quiescence factor and provide a 
translational framework for the delivery of this BMP ligand as a treatment strategy for 
PAH.  
 
Results 
BMP9 elicits endothelial-selective transcriptional regulation  
We sought to identify a BMP ligand for therapeutic delivery that would selectively 
and efficiently enhance canonical BMP signaling in the endothelium while 
minimizing the potential for deleterious off-target effects, such as the calcification of 
soft tissue28. As an initial screen, we stimulated human pulmonary arterial endothelial 
cells (PAECs) with BMP9, BMP2 or BMP6 and assessed changes in gene 
transcription by microarray. Unlike BMP2 and BMP6, which induced negligible gene 
expression, BMP9 induced the differential regulation of 1883 genes (adjusted P value 
< 0.05), including several key components of canonical BMP signaling such as ID1, 
ID2 and BMPR2 (Fig. 1a-c). Generally applicable gene-set enrichment (GAGE) 
analysis for common signaling pathways and cellular processes revealed TGF-β 
signaling as the only pathway to be significantly (P=0.0012) upregulated by BMP9. 
However, BMP9 also downregulated other pathways, including apoptotic cell 
signaling (Fig. 1d; Supplementary Fig. 1). Signaling pathway impact analysis 
(SPIA) of common signaling pathways confirmed the TGF-β pathway as the only 
pathway to be enhanced in response to BMP9 treatment, supporting a central role for 
the canonical Smad pathway in the actions of BMP9 (Fig. 1e). We obtained similar 
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results using blood outgrowth endothelial cells (BOECs) from healthy subjects, 
which, like PAECs, responded almost exclusively to BMP9 stimulation 
(Supplementary Fig. 2). Analysis of BMP9-induced gene expression for specific 
members of the TGF-β pathway revealed an enhancement of classical downstream 
targets of BMP signaling, whereas expression levels of TGF-β1 downstream targets, 
including PAI-1, Myc and CTGF, remained unchanged (Supplementary Fig. 3a). Of 
note, BMP9 did not alter the expression of a selected group of endothelial-derived 
paracrine factors and typical PASMC mitogens, including members of the PDGF and 
FGF families of cytokines (Supplementary Fig. 3b). 
Validation of BMP responsiveness in PAECs by immunoblotting confirmed 
robust induction of Smad1/5/8 phosphorylation, ID1 and ID3 in PAECs in response to 
BMP9 concentrations as low as 0.1 ng/mL. In contrast, other BMPs were much less 
effective over the range of doses tested (Fig. 1f, Supplementary Fig. 4b). As a 
further measure of endothelial selectivity, PASMCs displayed a modest response to 
BMP9 when compared to an equivalent dose range of other BMPs (Supplementary 
Fig. 4a,b). We observed similar responses in additional endothelial cell lines 
(Supplementary Fig. 4b). As a further measure of the endothelial selectivity of 
BMP9 in the pulmonary circulation, we stimulated freshly isolated rat pulmonary 
arteries ex vivo with BMP9 and assessed for induction of Smad1/5 phosphorylation. 
We observed phospho-Smad immunostaining exclusively in the endothelium, with no 
measurable signal in the underlying smooth muscle   (Supplementary Fig. 4c). 
  The array study also identified a notable capacity of BMP9 to induce BMPR2 
gene expression, which was validated by immunoblotting and qPCR (Fig. 1f-g). 
siRNA knockdown of Smad1, with or without Smad5 knockdown, eliminated the 
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capacity of BMP9 to enhance BMPR2 expression (Supplementary Fig. 5a-d), 
supporting the importance of canonical Smad signaling to this process. To confirm 
this finding, we identified a putative Smad binding site on the BMPR2 promoter 
(Supplementary Fig. 5e) and used chromatin immunoprecipitation in human 
microvascular endothelial cells (HMEC-1) to demonstrate p-Smad1/5 and Smad4 
binding to this region, which was lost following siRNA knockdown of Smad1 and 
enhanced in response to treatment with BMP9 (Fig. 1h). HMEC-1 cells transfected 
with a luciferase reporter construct downstream of a 5kb segment of the BMPR2 
promoter exhibited enhanced basal luciferase activity versus a control vector without 
the BMPR2 promoter region, which was further elevated in response to BMP9 
treatment (Fig. 1i). Mutation of the putative Smad binding region in the 5kb segment 
reduced both baseline luciferase activity and BMP9 regulation of the promoter. We 
did not observe a similar enhancement of BMPR2 expression in PASMCs in response 
to treatment with BMP9, BMP2 or BMP6 (Supplementary Fig. 5f).  
 
BMP9 prevents endothelial cell apoptosis and permeability 
As reported previously29, PAECs stimulated with TNFα in the presence of 
cyclohexamide exhibited elevated JNK phosphorylation as a part of an apoptotic 
signaling cascade (Fig. 2a). Pre-treatment of PAECs with BMP9 prevented JNK 
phosphorylation and blocked the induction of apoptosis, as demonstrated by 
immunoblotting for cleaved caspase-3 (Fig. 2b) and by flow cytometry for early 
apoptotic, Annexin-V+/PI– cells (Fig. 2c,d). Since BMP9 signals via complexes of the 
type I receptor ALK1 with either BMPR-II or ActR-II as the type II receptor30, we 
determined whether the anti-apoptotic effects of BMP9 were indeed BMPR-II 
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dependent. siRNA knockdown of BMPR-II (Fig. 2e) eliminated the capacity of 
BMP9 to prevent apoptosis when compared to controls (Fig. 2f,g). Importantly, 
siRNA knockdown of Smad1 and Smad5 also partially blocked the anti-apoptotic 
effect of BMP9, reinforcing the importance of canonical Smad signaling in this 
process (Supplementary Fig. 6). 
BOECs from healthy controls and individuals with PAH-associated mutations 
in BMPR2 were used as a surrogate for PAECs to determine the efficacy of BMP9 
therapy in the context of BMPR2 mutations. Although mutation-bearing BOECs 
displayed an increased susceptibility to apoptosis when compared to cells isolated 
from healthy control subjects (Fig. 3a), BMP9 blocked JNK phosphorylation (Fig. 
3b) and apoptosis in both control and mutation-bearing BOECs (Fig. 3a,c), 
supporting the benefit of this approach, even in the context of BMPR-II deficiency.   
We also examined the effect of BMP9 on endothelial barrier integrity (Fig. 
3d-g). LPS stimulation of control BOECs resulted in increased monolayer 
permeability that was blocked by the addition of BMP9.  BOECs with BMPR2 
mutations demonstrated greater permeability in response to LPS.  However, as with 
the apoptotic responses, heterozygous BMPR2 mutation in these cells did not prevent 
the capacity of BMP9 to block LPS-induced monolayer permeability. BMP9 also 
reduced the basal permeability of unstimulated, mutation bearing BOECs (Fig. 3f). 
We observed similar results in PAECs in response to TNFα or thrombin-induced 
permeability (Supplementary Fig. 7a). VE-cadherin staining demonstrated impaired 
cell-cell junctions in response to all three stimuli that was blocked by BMP9 (Fig. 3g, 
Supplementary Fig. 7b).  
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Bmpr2+/R899X mice develop age-related pulmonary hypertension 
In order to determine whether exogenous administration of BMP9 would be beneficial 
in a mouse model of PAH that mimics the genetics of human disease, we created a 
knock-in mouse, bearing the human disease-associated R899X premature stop 
mutation in exon 12 of the endogenous Bmpr2 locus (Supplementary Fig. 8a). As 
reported for Bmpr2 null mice31, mice homozygous for the R899X mutation were non-
viable. Heterozygous Bmpr2+/R899X mice developed normally and displayed reduced 
BMPR-II protein (Supplementary Fig. 8b) and mRNA (Supplementary Fig. 8c), 
consistent with an R899X mutation that leads to mRNA degradation by nonsense 
mediated mRNA decay (NMD) in humans32. We confirmed NMD of the R899X 
transcript in both mouse and human smooth muscle cells bearing the mutant allele 
(Supplementary Fig. 8d-i). Bmpr2+/R899X mice exhibited normal right ventricular 
systolic pressures (RVSP) at 3 months of age (Supplementary Fig. 9a), but 
developed elevated RVSP by 6 months (Fig. 4a). While this increase in RVSP was 
not accompanied by right ventricular hypertrophy (Fig. 4b), 6 month-old 
Bmpr2+/R899X mice did exhibit enhanced muscularization of peripheral pulmonary 
arteries in the lung (Fig. 4c,d). Further characterization of left ventricular function 
demonstrated no significant differences in left ventricular end diastolic pressure or 
cardiac output between 6 month-old Bmpr2+/R899X and WT controls (Supplementary 
Table 1). In contrast, 6 month-old Bmpr2+/– mice did not exhibit elevated RVSP or 
RV hypertrophy in our hands (Supplementary Fig. 9e-f). 
To examine the importance of canonical Smad signaling in this PAH model, 
we also assessed the pulmonary vascular phenotype of mice heterozygous for 
Smad133. Male Smad1+/– mice did not exhibit raised RVSP or RV hypertrophy at 3 or 
6 months (Fig. 4e,f; Supplementary Fig. 9b-d). However, the generation of 
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Bmpr2+/R899X/Smad1+/– compound heterozygotes resulted in mice that, by 6 months, 
developed more severe elevations in RVSP than those heterozygous for R899X alone 
(Fig. 4e). Unlike Bmpr2+/R899X mice, this more pronounced elevation in RVSP was 
also accompanied by right ventricular hypertrophy in Bmpr2+/R899X/Smad1+/– mice 
when compared to WT controls (Fig. 4F). Both Bmpr2+/R899X and 
Bmpr2+/R899X/Smad1+/– compound heterozygous mice exhibited reduced BMPR-II 
protein and pulmonary Smad1/5 phosphorylation compared to WT littermate controls 
(Supplementary Fig. 9e-g).  
 
BMP9 reverses pulmonary hypertension in Bmpr2+/R899X mice 
Treatment of 6 month-old Bmpr2+/R899X mice with BMP9 (75 ng daily, i.p.) for 4 
weeks reversed all indices of PAH in this chronic disease model, returning RVSP to 
the level seen in WT mice (Fig. 4a) and reversing the enhanced pulmonary arterial 
muscularization in these mice (Fig. 4c,d). The dose selection was based on an initial, 
7-day chronic dose-ranging study in rats (Supplementary Fig. 10a) and translated to 
mice on a weight/weight basis (Supplementary Fig. 10b).  
We also used pulmonary endothelial cells from WT and Bmpr2+/R899X mice to 
assess the capacity of BMP9 to enhance monolayer integrity in vitro. As with BMPR2 
mutation-bearing BOECs, endothelial monolayers from Bmpr2+/R899X mice displayed 
increased permeability both at baseline and following LPS stimulation.  BMP9 
prevented LPS-induced permeability in endothelial monolayers from both WT and 
Bmpr2+/R899X mice (Fig. 4g; Supplementary Fig. 10c,d). In vivo, Bmpr2+/R899X and 
WT mice injected with LPS developed pulmonary vascular leak, quantified by 
extravasation of Evans blue dye into lung tissue (Fig. 4h). Bmpr2+/R899X mice 
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demonstrated increased dye extravasation compared to WT littermates, which was 
blocked with BMP9 to a similar degree in both groups (Fig. 4i).   
To further exclude the possibility that BMP9 was acting through a direct effect 
on smooth muscle, we isolated PASMCs from WT and Bmpr2+/R899X mice. While 
BMP4 reduced PASMC proliferation, BMP9 had no effect (Supplementary Fig. 
10e,f).  
 
BMP9 reverses monocrotaline-induced pulmonary hypertension 
We assessed the efficacy of BMP9 treatment in the monocrotaline rat model of PAH, 
a non-genetic model of disease in which reduction of BMPR-II expression is a central 
feature7,34. BMP9 treatment for 21 days (600 ng/day, i.p.) immediately following 
exposure to monocrotaline prevented elevation of RVSP, right ventricular 
hypertrophy and pulmonary arterial muscularization (Fig. 5a-d). In a protocol where 
BMP9 dosing was commenced 3 weeks after monocrotaline, in the presence of the 
established PAH, two weeks of daily BMP9 treatment inhibited the progression of 
PAH (Fig. 5c-f). In agreement with our previous reports, rats treated with 
monocrotaline displayed reduced lung BMPR-II protein levels and impaired canonical 
BMP signaling (Supplementary Fig. 11a-d).  Treatment with BMP9 from days 0 to 
21 restored BMPR-II levels and downstream signaling to near normal levels.  
Endothelial apoptosis is believed to be a primary factor in the initiation of 
PAH models16,17 and human disease15. Staining of lung tissue for cleaved caspase-3 
not only revealed enhanced pulmonary endothelial cell apoptosis at five days post-
monocrotaline, but also in established disease at three weeks post-monocrotaline (Fig. 
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5g,h). Daily administration of BMP9 prevented enhanced apoptosis at both time 
points. Immunoblotting of whole lung lysates confirmed a reduction in total cleaved 
caspase-3 in response to BMP9 at both three and five weeks post-monocrotaline 
(Supplementary Fig. 11e). 
 
BMP9 reverses Sugen-hypoxia induced pulmonary hypertension  
We also examined the efficacy of BMP9 in the more severe PAH model of rats 
exposed to chronic hypoxia in combination with the VEGF receptor blocker SU-
541617 (Fig. 6a). Rats given SU-5416 and exposed to three weeks of hypoxia (10% 
O2) and an additional 5 weeks of normoxia developed severe pulmonary hypertension 
and right ventricular hypertrophy (Fig. 6b-c) as well as extensive pulmonary arterial 
muscularization (Fig. 6d-e). Daily BMP9 (600 ng/day, i.p.) from weeks 8 to 11 
resulted in a reversal of established disease, including a reduction in RVSP, RV 
hypertrophy and vascular remodeling when compared to saline-treated controls (Fig. 
6b-e).  
Established disease was also accompanied by the concurrent formation of both 
angio-obliterative lesions (Fig. 6f,h) and heightened endothelial cell apoptosis (Fig. 
6g), as well as reduced Smad1/5 phosphorylation (Supplementary Fig. 12a-b), all of 
which were reversed by BMP9. Immunoblotting of whole lung lysates for cleaved 
caspase-3 and PCNA further supported the capacity of BMP9 to simultaneously 
prevent excessive endothelial cell apoptosis and pathological angiogenesis in this 
model (Supplementary Fig. 12a). While BMP9 did not reverse elevated VEGFA 
gene expression in the lungs of rats treated with SU-5416 and hypoxia, it did block 
VEGF-induced endothelial cell proliferation and tube formation in vitro 
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(Supplementary Fig. 12c-i). Assessment of LV function revealed no significant 
changes in cardiac output in diseased animals given BMP9 or saline when compared 
to healthy controls (Supplementary Table 1). 
Similarly, mice given SU-5416 and exposed to three weeks of hypoxia (10% 
O2) developed moderate-to-severe pulmonary hypertension and right ventricular 
hypertrophy, accompanied by increased pulmonary arteriolar muscularization 
(Supplementary Fig. 13a-c).  Administration of BMP9 (75 ng/day, i.p.) throughout 
the period of treatment with SU-5416 and hypoxia resulted in normalization of right 
ventricular systolic pressure and right ventricular mass, and abrogated the 
muscularization of small arterioles. Treatment of mice with BMP9 did not result in 
heterotopic ossification at the sites of i.p. injection, based on x-ray and micro-CT 
analysis (Supplementary Fig. 13d).  Moreover, daily intramuscular injection of mice 
with BMP9 (75 ng/day) for 3 weeks failed to elicit intramuscular heterotopic 
ossification (Supplementary Fig. 13e). 
 
Discussion 
We report the first use of a BMP ligand to target and enhance endothelial BMPR-II 
signaling and reverse established PAH in animal models of disease. This work is also 
the first to show that mice heterozygous for a human disease causing mutation are 
susceptible to PAH, providing a new genetic model for this disease that, unlike 
previous models, closely mimics the human genetics of PAH. 
One challenge associated with therapeutic application of BMPs for the treatment 
of PAH is the identification of a ligand that preferentially targets the pulmonary 
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endothelium. Our array screen of PAECs treated with different BMP ligands 
demonstrated the superiority of BMP9 for stimulating the pulmonary endothelium. Of 
note is our observation that BMP2, 4 and 6 possess minimal ability to stimulate 
PAECs, which at first sight contrasts with other previously published findings. This 
discrepancy can be largely accounted for by differences in the concentrations of 
BMPs used. The majority of papers describing a response of endothelial cells to 
BMP2, 4 or 6 used concentrations in excess of 10ng/ml and often use a range of 50-
200 ng/ml15,35. Here we show the response of PAECs to BMP9 is already maximal at 
1 ng/ml. These findings demonstrate that other BMPs may be used to stimulate the 
endothelium, but only at high doses that will have no selectivity for the endothelium 
and likely promote heterotopic ossification. In contrast, BMP9 allows for selective 
stimulation of canonical BMP signalling in pulmonary endothelial cells at 
concentrations that do not induce signaling in PASMCs and do not promote 
ossification. As ALK1 is also expressed in hepatocytes, mesenchymal cells, 
chondrocytes and cardiomyocytes, we cannot categorically exclude non-endothelial 
mechanisms of BMP9 treatment. 
In vitro and in vivo studies confirmed the capacity of BMP9 to block apoptosis 
and enhance vascular stability, two pathways critically dysregulated in the 
pathogenesis of PAH15-20. The ability of BMP9 to prevent endothelial apoptosis in 
vitro is in agreement with previous studies that reported the anti-apoptotic effect of 
various BMP ligands15,36. Despite the fact that this action of BMP9 is dependent on 
BMPR-II, we were able to show that BMP9 provides protection in BMPR2 mutation-
bearing BOECs, presumably due to increased ligand interaction and signaling via the 
wild type receptor. We demonstrate that BMP9 inhibited endothelial permeability 
induced by a variety of agents relevant to PAH. Endothelial permeability is 
 15
increasingly implicated in PAH pathobiology and a recent study identified that loss of 
BMPR-II promotes SRC-dependent caveolar trafficking defects in heritable PAH as a 
potential mechanism37.  
Beyond the direct effects of BMP9 on endothelial cell function, we demonstrate 
the capacity of BMP9 to increase BMPR-II levels via a Smad-binding region on the 
BMPR2 promoter. In canonical BMP signaling, interactions of ligands with 
heterodimers of type I and type II receptors leads to phosphorylation of a restricted set 
of receptor activated Smad proteins (Smads 1,5 and 8). However, non-Smad mediated 
BMP signaling is involved in certain cellular responses. Despite the recent 
identification of rare mutations in Smad1 and Smad8 in individuals with PAH38,39, the 
relative contribution of Smad and non-Smad mediated signaling to the pathobiology 
of PAH remains uncertain. Our observation that compound heterozygous mice, 
bearing loss-of-function mutations in both Bmpr2 and Smad1, develop more severe 
spontaneous PAH than that observed in mice heterozygous for Bmpr2 alone supports 
a central role for the canonical BMPR-II/Smad signaling pathway in PAH. This is 
supported by a previous study showing that conditional deletion of Smad1 in 
endothelial cells in mice promotes the development of PAH40. 
Our report of the spontaneous development of PAH in the Bmpr2+/R899X knock-in 
mouse is a major development, which for the first time provides an experimental 
model of disease that closely mimics the human genetics of PAH, leading to NMD of 
the mutant transcript. Although Bmpr2+/R899X mice spontaneously develop elevated 
right ventricular systolic pressures and enhanced pulmonary arteriolar 
muscularization at 6 months of age, these changes were not accompanied by right 
ventricular hypertrophy. One possibility is that the modest increase in RVSP in these 
mice (~35mmHg) was not sufficient to induce measurable RV hypertrophy. This 
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possibility is supported by the fact that compound Bmpr2+/R899X/Smad1+/– 
heterozygotes did develop RV hypertrophy in response to a more severe elevation of 
RVSP. Alternatively, a recent reports in a pulmonary arterial banding model of RV 
hypertrophy showed that the transgenic expression of a stabilized form of mutant 
Bmpr2-R899X in the heart results in reduced RV remodeling associated with intra-
cardiomyocyte lipid deposition41. It is noteworthy that aged Bmpr2+/R899X mice are 
susceptible to PAH, whereas Bmpr2 heterozygous null mice are not. There is no clear 
explanation for this observation, since both would be expected to result in 
haploinsufficiency. It remains possible that incomplete NMD of the mutant transcript 
in Bmpr2+/R899X mice plays a role, although we found no evidence for this. 
The finding that BMP9 treatment reverses established disease in three animal 
models of PAH is critical, as any viable treatment will need to be effective in a patient 
population that typically presents with advanced disease. The capacity of BMP9 to 
reverse disease in the Sugen-hypoxia model is a particularly important indicator of the 
clinical suitability of this treatment strategy, as it is the only model to recapitulate the 
intimal lesions and advanced vascular remodeling observed in individuals with PAH.  
In these models, we have shown that, as in our cultured endothelial cells, BMP9 
promotes vascular stability by simultaneously preventing apoptosis and blocking 
pathological angioproliferation. Our observation of increased endothelial apoptosis at 
later time points in both the monocrotaline and Sugen-hypoxia rat models support the 
suggestion that endothelial apoptosis is not only a driving factor in disease onset, but 
an ongoing phenomenon in established disease, occuring concurrently with 
pathological angioproliferation. This finding is supported by our observation that 
BMPR2 mutation-bearing BOECs are more susceptible to apoptotic stimuli even 
when isolated from individuals with established PAH. 
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 In conclusion, our work provides proof-of-concept for the treatment of PAH 
through the direct enhancement of endothelial BMPR-II signaling with BMP9.  
BMP9 not only protects pulmonary arterial endothelial cells from apoptosis and 
promotes vascular stability, but also increases BMPR2 gene expression, allowing for 
further enhancement of BMPR-II signaling. These effects were still observed in cells 
derived from individuals bearing mutations in BMPR2, suggesting that this treatment 
might be efficacious in PAH patients with or without a mutation. Taken together, our 
findings suggest that approaches based on targeting the canonical endothelial BMPR-
II/ALK1 complex using recombinant ligands or small molecule receptor agonists may 
provide a promising new approach for the treatment of PAH. 
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Figure Legends 
Figure 1: BMP9 preferentially stimulates hPAECs. Volcano plots of differentially 
expressed genes in PAECs treated with (a) 1 ng/mL BMP9, (b) 10 ng/mL BMP6 or 
(c) 10 ng/mL BMP2 versus control after fitting linear models and adjusting P values 
for multiple testing (FDR). Differentially expressed genes of the TGF-β pathway are 
highlighted in grey. Dashed lines represent an adjusted P value of 0.05 and a fold 
change of +/– 1x. (d) Heat map showing whole gene-set perturbation (test statistics) 
of regulated pathways in PAECs following BMP9 treatment. (e) Signaling pathway 
impact analysis (SPIA) to detect alterations in common signaling pathways in PAECs 
in response to BMP9 treatment. Corrected for false discovery rate. (f) Immunoblotting 
for phosphorylated Smad1/5/8, Id1, Id3, BMPR-II and β-actin in PAECs cultured 
with or without varying concentrations of BMP9, BMP4 and BMP6 ligand for 2 
hours. Representative of 3 experiments. (g) Expression of BMPR2 in PAECs with or 
without treatment with 10 ng/mL BMP9 for 24 hours (n=3; Student’s t test). (h) 
Representative agarose gels for products from chromatin immunoprecipitation on 
lysates from HMEC-1 cells (top) without treatment, (middle) 72 hours after siRNA 
knockdown of SMAD1 or (bottom) following a 24 hour treatment with 1 ng/mL 
BMP9. (i) Luciferase activity in HMEC-1 lysates transfected with a luciferase 
reporter construct with or without an upstream 5kb portion of the BMPR2 promoter 
with or without mutation of the putative Smad binding region. Cells bearing the 
reporter construct were treated with 10 ng/mL BMP9 for 24 hours (n=3; 1-way 
ANOVA, Tukey’s post test). ***P<0.001, **P<0.01, *P<0.05.  Mean +/– SEM. 
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Figure 2: BMP9 prevents apoptosis in human PAECs via BMPR-II. 
Representative immunoblots and densitometric analysis for (a) phosphorylated JNK 
(n=4) and (b) cleaved caspase 3 (n=3) in human PAECs cultured with or without 
BMP9 (5 ng/mL) for 16 hours prior to an apoptotic stimulus with TNFα (10 ng/mL) 
and cyclohexamide (20 μg/mL) (1-way ANOVA, Tukey’s post test). (c) 
Representative flow cytometry plots of human PAECs stained with Annexin-V and 
propidium iodide (PI) with or without BMP9 pre-treatment and apoptotic stimulus. 
(d) Quantification of apoptotic (Annexin-V+/PI–) PAECs (n=5); 1-way ANOVA, 
Tukey’s post test). (e) Validation of siRNA knockdown in PAECs by immunoblotting 
for BMPR-II following treatment with either Dharmafect 1 transfection reagent 
(DH1), siRNA for BMPR2 (siBMPR2) or a pooled siRNA control (siCP). (f) 
Cytometric quantification of apoptosis by staining for Annexin-V and PI in PAECs 
treated with DH1 alone, siBMPR2 or siCP and cultured with or without BMP9 pre-
treatment and apoptotic stimulus (n=6 for DH1 and siBMPR-II, n=5 for siCP; 1-way 
ANOVA for each siRNA group, Tukey’s post test). (g) Representative immunoblot 
and densitometric analysis of cleaved caspase-3 in PAECs following siRNA 
transfection with or without BMP9 pre-treatment and apoptotic stimulus. (n=3; 1-way 
ANOVA for each siRNA group, Tukey’s post test). All blots were re-probed for α-
tubulin as a loading control. ***P<0.001, **P<0.01, * P<0.05. Mean +/– SEM. 
Figure 3: BMP9 prevents apoptosis and promotes monolayer integrity in BOECs 
with and without BMPR-II mutations. (a) Quantification of apoptotic (Annexin-
V+/PI–) control (n=5 individuals) and BMPR2 mutation-bearing BOECs (n=6 
individuals) after culture with or without BMP9 (5 ng/mL) for 16 hours prior to the 
addition of TNFα (10 ng/mL) and cyclohexamide (20 μg/mL) for 6 hours. (b-c) 
Immunoblotting for (b) phosphorylated JNK and (c) cleaved caspase-3 in control and 
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BMPR2 mutation-bearing BOECs with or without BMP9 pre-treatment and apoptotic 
stimulus. Representative of five immunoblots. All blots were re-probed for α-tubulin 
as a loading control. (d-f) Permeability of (d) control or (e) BMPR2 mutation-bearing 
BOEC monolayers to HRP, assessed as a measure of colorimetric absorbance after 
incubation periods ranging from 30 minutes to 2 hours with or without BMP9 
(20 ng/mL) and/or LPS (400 ng/mL) (f) Quantification of monolayer permeability at 
2 hours post-LPS. (n=4 individuals per group). AU: Arbitraty units. ***P<0.001, 
**P<0.01, *P<0.05, 1-way ANOVA, repeated measures Tukey’s post test for Control 
or BMPR2 Mutation BOECs; ###P<0.001, ##P<0.01, 1-way ANOVA, Tukey’s post 
test for all groups. Mean +/– SEM. (g) Representative immunofluorescence images of 
PAECs stained for VE-cadherin following 24 hour culture with or without BMP9 
(10 ng/mL) and/or LPS (400 ng/mL). Scale bars 10 μm. 
 
Figure 4: Pulmonary hypertension in Bmpr2+/R899X knock-in mice is reversed by 
BMP9. (a) Assessment of right ventricular systolic pressure (RVSP) in 6-month-old, 
naive Bmpr2+/R899X mice (n=21, 11 male, 10 female) and WT littermate controls 
(n=23, 13 male, 10 female) or with 4 weeks of BMP9 treatment (75 ng/day, i.p., n=10 
(9 male, 1 female) for WT and n=11 (9 male, 2 female) for Bmpr2+/R899X; 1-way 
ANOVA, Tukey’s post test). (b) Right ventricular hypertrophy (Fulton index, ratio of 
RV weight over LV and septal weight) in the same animals as a (not significant). (c) 
Quantitative assessment of pulmonary arterial muscularization in the same groups as 
a. Displayed as a non-, partially- and fully-muscularized arteries as a percentage of 
total alveolar wall and duct arteries (n=12 (6 male, 6 female) for naïve WT and 
Bmpr2+/R899X mice; with BMP9 treatment n=3 (2 male, 1 female) for WT and n=5 (3 
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male, 2 female) for Bmpr2+/R899X; 1-way ANOVA, Tukey’s post test). (d) 
Representative images of immunohistochemical staining for smooth muscle α-actin in 
lung sections from WT and Bmpr2+/R899X mice with or without BMP9 treatment. (e) 
Assessment of RVSP and (f) RV hypertrophy in male 6 month-old WT (n=16), 
Smad1+/– (n=9), Bmpr2+/R899X (n=10) and compound Bmpr2+/R899X/Smad1+/– 
heterozygotes (n=10; 1-way ANOVA, Tukey’s post test). (g) Quantification of 
monolayer permeability at 2 hours post-LPS. (n=3; 1-way ANOVA, repeated 
measures Tukey’s post test for WT or Bmpr2+/R899X cells; #P<0.05, 1-way ANOVA, 
Tukey’s post test for all groups). AU: Arbitrary units. (h) Images of lungs isolated 
from mice injected with 2 mg/kg LPS or vehicle and either 36.79 ng/25g BMP9 or 
vehicle (all i.p.)  22 hours prior to the i.p. injection of Evans blue dye, which was 
delivered 2 hours prior to sacrifice. (i) Quantitative assessment of extravascular Evans 
blue dye in the lungs of the mice described in h (Control: n=7 (5 male, 2 female) for 
WT, n=9 (4 male, 5 female) for Bmpr2+/R899X; LPS: n=8 (5 male, 3 female) for WT, 
n=10 (6 male, 4 female) for Bmpr2+/R899X; LPS + BMP9: n=8 (4 male, 4 female) for 
WT, n=9 (5 male, 4 female) for Bmpr2+/R899X; 1-way ANOVA, Tukey’s post test for 
WT or Bmpr2+/R899X mice; #P<0.05, 1-way ANOVA, Tukey’s post test for all groups). 
***P<0.001, **P<0.01, *P<0.05. Mean +/– SEM. 
 
Figure 5: BMP9 reverses established monocrotaline-induced pulmonary 
hypertension and prevents endothelial cell apoptosis in rats. (a) Assessment of 
right ventricular systolic pressure (RVSP) and (b) RV hypertrophy (Fulton index) in 
rats on a prevention protocol given vehicle (n=6) or monocrotaline (60 mg/kg, i.p.) 
and treated with BMP9 (n=7, 600 ng/day, i.p.) or vehicle (n=8) from days 0 to 21 
post-MCT (1-way ANOVA, Tukey’s post test). (c) Quantitative assessment of 
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pulmonary arterial muscularization in control rats or rats given monocrotaline, 
followed by daily injections with saline or BMP9 in a prevention (days 0-21 post-
MCT) or reversal (days 21-35 post-MCT) protocol. Displayed as non-, partially- and 
fully-muscularized arteries as a percentage of total alveolar wall and duct arteries 
(n=5 for prevention, n=6 for reversal; 1-way ANOVA, Tukey’s post test for fully 
muscularized vessels). (d) Immunohistochemical staining for smooth muscle α-actin 
in lung sections from the rats as described in c. Scale bars 100 μm. (e) Assessment of 
right ventricular systolic pressure (RVSP) and (f) RV hypertrophy (Fulton index) in 
rats on a reversal protocol given vehicle (n=4) or monocrotaline (40 mg/kg, i.p.) and 
treated with BMP9 (n=10, 600 ng/day) or vehicle (n=9) from days 21 to 35 post-MCT 
(t test on 35 day groups treated with saline or BMP9). (g) Representative images of 
immunohistochemical staining for von Willebrand Factor (upper) and cleaved 
caspase-3 (lower) in lung sections from rats given vehicle control or monocrotaline 
(60 mg/kg, i.p.), treated with BMP9 (600 ng/day, i.p.) or saline from day 0 and 
sacrificed on day 5 post-MCT. Scale bars 50 μm. (h) Quantification of cleaved 
caspase-3 positive endothelial cells in lung sections from the groups described in a, b 
and g and sacrificed on days 2, 5 or 21 post-MCT (n=11 for Control, n=6 for days 2 
and 5 post-MCT, n=5 for day 21 post-MCT; 1-way ANOVA, Tukey’s post test). 
***P<0.001, **P<0.01, *P<0.05. Mean +/– SEM. 
 
Figure 6: BMP9 reverses established pulmonary hypertension in rats in response 
to treatment with the VEGF receptor inhibitior SU-5416 in combination with 
chronic hypoxia. (a) Rats were given vehicle injections and maintained in normoxia 
(n=4) or challenged with SU-5416 (20 mg/kg, i.p.) and 3 weeks hypoxia (10% O2) 
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prior to 5 weeks normoxia and assessment at 8 weeks (n=7) or at 11 weeks following 
daily treatment with saline vehicle (n=11) or BMP9 (n=11; 600 ng/ day, i.p.). (b) 
Assessment of right ventricular systolic pressure (RVSP) and (c) RV hypertrophy 
(Fulton index) for the rats described in a (1-way ANOVA, Tukey’s post test). (d) 
Quantification of non-, partially- and fully-muscularized arteries as a percentage of 
total alveolar wall and duct arteries (n=4 for control, n=6 for all other groups; 1-way 
ANOVA, Tukey’s post test for fully muscularized vessels). (e) Assessment of 
pulmonary arterial wall thickness as a percentage of luminal diameter (n=4 for 
control, n=6 for all other groups; 1-way ANOVA, Tukey’s post test). (f) 
Quantification of neointimal lesion frequency in the lungs of the rats described in a 
(n=3 for control, n=6 for all other groups; 1-way ANOVA, Tukey’s post test). (g) 
Quantification of cleaved caspase-3 positive endothelial cells in lung sections from 
the groups described in a (n=3 for control, n=6 for all other groups; 1-way ANOVA, 
Tukey’s post test). ***P<0.001, **P<0.01, *P<0.05. Mean +/– SEM. (h) Neointima 
formation in the lungs of the rats described in a. Lung sections were stained for 
smooth muscle α-actin (SMA) or with elastic van Gieson (EVG) stain. Scale bar = 
50μm. 
 
Online Methods 
Cell Culture  
Human ECs were purchased from Lonza (Basel, Switzerland). PAECs, HUVECs, 
HAECs and HMEC-1 cells were cultured in EGM-2 with 2% FBS (Lonza), as per 
supplier’s instructions. Human BOECs were generated from 40-80 mL peripheral 
blood, as described previously42. BOECs were cultured in EGM-2MV with 10% 
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standard grade FBS (Life Technologies, Carlsbad, CA) and were used for experiments 
between passages 4 and 8. Unless specified otherwise, treatment of human endothelial 
cells with BMPs was performed in EBM-2 (Lonza) with 0.1% FBS.  
The endothelial nature of BOECs was assessed by flow cytometery for 
endothelial surface marker expression as described previously42. All cell lines were 
routinely tested for mycoplasma contamination. For BOEC generation, all blood 
donors provided informed consent in accordance with human study 07/H0306/134 
(Cambridgeshire 3 Research Ethics Committee). Information on the specific BMPR2 
mutations present in BOECs is specified in Supplementary Table 2. 
 Mouse lung microvascular endothelial cells were isolated as described 
previously43 with minor modifications.  Briefly, minced lung tissue was digested for 
30 minutes at 37ºC in 2mg/mL Collagenase I (Sigma Aldrich, St. Louis, MO), 
dissolved in DPBS with calcium and magnesium and filtered through a 70μm cell 
strainer. The resultant cell suspension was incubated for 10 minutes at room 
temperature with sheep anti-rat IgG Dynabeads (Life Technologies), pre-conjugated 
with rat anti-mouse PECAM-1 (BD-Pharmingen, Franklin Lakes, NJ). Magnetically 
isolated cells were washed multiple times DMEM and plated on tissue culture plates 
pre-coated with 0.1% gelatin (Sigma) for 24 hours in Endothelial Growth Medium, 
consisting of DMEM with 20% FBS, 1x Penicillin-Streptomycin-Glutamine (Life 
Technologies), 0.1mg/mL heparin (Sigma) and 0.1mg/mL Endothelial Cell Growth 
Factor (Biomed Tech Inc, Ward Hill, MA).  After 24 hours, cultures were washed to 
remove non-adherent cells and allowed to grow for 5-9 days until near confluent. 
Cells were then trypsinized and endothelial cells were purified by a second round of 
positive magnetic selection with Dynabeads. Resultant endothelial cells, which grow 
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with a typical cobblestone morphology, were then re-plated on gelatin coated plates in 
Endothelial Growth Medium. 
 Human and mouse PASMCs were isolated and cultured as described 
previously.44 Unless specified otherwise, tretament of PASMCs with BMPs was 
performed in DMEM with 0.1% FBS.  
Microarray 
PAECs (n=4) or BOECs (n=3) from healthy subjects were quiesced in M199 media 
with 0.1% FBS for 12 hours prior to a 4 hour stimulation in new media with vehicle, 1 
ng/mL BMP9, 10 ng/mL BMP2 or 10 ng/mL BMP6 (all from R&D Systems, 
Minneapolis, MN). Cell monolayers were lysed in Trizol and purified mRNA was 
hybridized to Human Genome U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, 
CA). Quality control, background correction and normalization were performed using 
R/Bioconductor (http://bioconductor.org). Differential gene expression was assessed 
by fitting linear models and resulting p-values were adjusted for multiple testing45. 
Enrichment of gene-sets was determined using Generally Applicable Gene-set 
Enrichment (GAGE)46 and Signaling Pathway Impact Analysis (SPIA)47. Pathway 
diagrams were generated with the pathviews package48. The pathway maps of interest, 
i.e. "Environmental Information Processing" and “Cellular Processes” were retrieved 
from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Microarray 
data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under 
accession number E-MTAB-2495. 
 
siRNA knockdown and qPCR 
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Cells were maintained in Optimem serum free medium (Life Technologies) for 3 
hours prior to the addition of Dharmafect 1 transfection reagent with or without 
siRNAs for Smad1, Smad5 or BMPR2 or a control pool of oligonucleotides (all 
Thermo Fisher, Waltham, MA) for 4 hours. After siRNA treatment, cells were 
returned to culture media for 24 hours prior to use. qPCR for Smad1, Smad5, BMPR2 
or VEGFA mRNA was performed as described previously30 and presented relative to 
GAPDH, β-2 microglobulin, HPRT, β-actin, or a combination of these housekeeping 
genes. 
 
Western Blotting 
After the indicated duration of treatment, cells were lysed in phosphate buffered 
saline (PBS) containing 50mM Tris pH 8.0, 1% igepal, 0.1% SDS, 0.5% sodium 
deoxycholate and Roche complete protease inhibitor cocktail (Roche, Basel, 
Switzerland). Lysates were sonicated and frozen at -80°C until used. Cell lysates (20-
40μg total protein) were separated on reducing SDS-PAGE gels and proteins were 
transferred to polyvinylidene fluoride membranes by semi-dry blotting. Membranes 
were then blocked and probed with rabbit polyclonal antibodies towards JNK 
(catalogue # 9252), phospho-JNK (catalogue # 9251), Smad1 (catalogue # 9743), 
phospho-Smad1/5/8 (catalogue # 9511, all Cell Signaling Technology, Danvers, MA) 
or PCNA (catalogue # ab18197, Abcam, Cambridge, UK),  rabbit monoclonal 
antibodies towards Caspase-3 (clone 8G10), cleaved Caspase-3 (clone 5A1E), 
phosphorylated Smad1/5 (clone 41D10, all Cell Signaling Technology, Danvers, 
MA), Smad5 (clone EP619Y, Epitomics, Burlingame, CA), Id1 (clone 195-14) or Id3 
(clone 17-3, both CalBioreagents, San Mateo, CA) or a mouse monoclonal antibody 
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towards BMPR-II (clone 18/BMPR-II, BD Transduction Laboratories, Franklin 
Lakes, NJ). As a loading control, all blots were re-probed with a monoclonal antibody 
towards either α-tubulin (clone DM1A) or β-actin (clone AC-15, Sigma). 
Densitometry was performed using ImageJ software. 
 
Chromatin Immunoprecipitation (ChIP) Assay 
ChIP assays were performed using a chromatin immunoprecipitation assay kit 
(Millipore, Billerica, MA) in accordance with the manufacturer's instructions. HMEC-
1 cells at 80-90% confluency were assayed either at baseline, 72 hours after siRNA 
knockdown of Smad1 or following a 24 hour stimulation with 1 ng/mL BMP9. Cells 
were cross-linked with 1% formaldehyde for 10 minutes at 37⁰C. 125mM glycine was 
added to block cross-linking. Cells were then rinsed with PBS and lysed in 200µl 
buffer containing 1ug/ml aprotinin, pepstatin, and 1mM phenylmethylsulfonul 
fluoride. Chromatin samples were sonicated with 4 sets of 10-second pulses on wet 
ice using a Cole Parmer, High Intensity Ultrasonic Processor/Sonicater, 50-watt 
model equipped with a 2mm tip and set to 30% maximum power to reduce the DNA 
length to 200-1000bp. The sonicated lysate was then diluted to 2ml with dilution 
buffer containing a protease inhibitor cocktail. After preclearing with salmon sperm 
DNA/Protein A-agarose for 1h at 4⁰C, 20µl (1%) of this solution was removed for 
later PCR analysis (input). 2µg of the immunoprecipitating antibodies towards C-
terminal phospho-Smad1/5 or Smad4 (catalogue # 9515, Cell Signaling Technology) 
were added to the remaining sample (for the negative control, rabbit polyclonal IgG 
was added), and the sonicated lysates were incubated overnight at 4⁰C. Immune 
complexes were collected with 60µl of salmon sperm DNA/Protein A-agarose (1h at 
4⁰C), and agarose beads were washed with solutions of increasing ionic strength. 
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After a final wash, bound immune complexes were eluted in a freshly prepared 
solution of 1% SDS, 0.1M NaHCO3, and cross-links were reversed in the samples 
(and the input from the sonicated lysates) by heating at 65⁰C overnight. Samples were 
then treated with Proteinase K, and DNA was phenol/chloroform-extracted and 
precipitated. DNA was resuspended in 20µl H2O, and 1µl was used for detection of 
the BMPR2 promoter by PCR using the oligonucleotides 
5'-GAACACATCAAAGGGGTGGT-3' and 5'-GTGGCCTTTCTCCTTCACAC-3', 
which together amplify 350bp spanning from -1797 to -1448 of the promoter region.  
DNA from the input was resuspended in 20µl, and 1µl was used for PCR. 
 
BMPR2 Promoter Constructs 
A 5kb fragment of the human BMPR2 promoter was generated by polymerase chain 
reaction (PCR) from BAC clone RP11-68606. A 5' primer (5’-GCG CGA GCT CTA 
GTC CTC CCT GCC CCT TAT-3’), including a Sac I site for subcloning, and a 3' 
primer (5'-GCG CAA GCT TAG CAG GAT GGT CCA TGG TAG-3') initiating 
59bp upstream of the transcription start site and containing a Hind III site, were used. 
The amplified product was purified and cloned into the Sac I/Hind III-digested 
promoter-deficient reporter vector pGL3-basic (Promega, Madison, WI) to give the 
BMPR2-luc construct. The putative Smad binding site on the BMPR2 promoter was 
mutated using the PCR-based QuickChange Site-Directed Mutagenesis kit 
(Stratagene, La Jolla, CA) and the following primers Fwd: 
5’-GCTCTGCACCACAGGCTAGAGtgAtcCAGGGCCGGGAAGAG-3’; Rev: 
5’-CTCTTCCCGGCCCTGgaTcaCTCTAGCCTGTGGTGCAGAGC-3’, with the 
binding site indicated in bold and the desired point mutations indicated in lowercase. 
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PCR products were digested with Dpn I to elimate parental DNA. Recombinant DNA 
was verified by sequencing. 
 
Transfection of HMEC-1 cells 
HMEC-1 cells were seeded onto 24-well plates at a density of 8x104 cells per well 24 
hours before transfection. The transfection was performed with LipofectAMINE2000 
reagent (Invitrogen, UK). Typically 1µg of plasmid DNA was mixed with 2µl of 
LipofectAMINE2000.  Fresh culture medium was changed 24h after transfection.  48 
hours post-transfection, cells were washed with PBS and lysed. Nuclear-free 
supernatants were analysed for luciferase reporter gene activity (Roche Molecular 
Biochemicals, Germany) and corrected for protein content. 
 
Induction of and assessment of apoptosis by Annexin-V and Propidium Iodide 
staining 
Sixteen hours prior to the addition of an apoptotic stimulus, PAECs or BOECs were 
transferred into EBM-2 basal media (Lonza) with 2% FBS, 100 U/mL penicillin, 100 
mg/mL streptomycin and 0.25 mg/mL amphotericin B, but without any growth factor 
supplements.  During this incubation, cells were maintained with or without 5 ng/mL 
BMP9 for indicated period.  Following the 16-hour incubation, cells were either left 
unstimulated or treated for 3 or 6 hours with 10 ng/ml TNFα and 20 μg/mL 
cyclohexamide to induce apoptosis. For measurement of total and phospho-JNK, cells 
were lysed after 3 hours and lysates were assessed by immunoblotting. For 
assessment of apoptosis, cells were incubated for 6 hours after the apoptotic stimulus 
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and either lysed for the assessment of cleaved caspase-3 by immunoblotting or 
trypsinized, stained with FITC-conjugated annexin-V and propidium iodide (PI, BD 
Biosciences) as per manufacturer’s instructions and assessed by flow cytometry. 
Apoptotic cells were considered to be positive for annexin-V and negative for PI. 
 
Assessment of endothelial monolayer permeability 
Monolayer permeability was assessed as described previously49. Briefly, transwell 
inserts  (Corning, Corning, NY) were coated for 1 hour at 37ºC with 0.1 mg/mL 
bovine skin collagen (Sigma), washed with water 2 times and rinsed with medium 
prior to plating cells. Cells (4x105 in 100 µl complete EGM-2 medium) were plated in 
the top chamber and 700 µl of medium was added to the bottom chamber 24 hours 
prior to the addition of fresh medium to both chambers, with or without 10 or 20 
ng/mL BMP9 in the upper chamber (as indicated).  After 30 minutes, 25 nM 
horseradish peroxidase was added to the top chamber, with or without 0.4ug/ml LPS 
(Sigma), 1U/mL thrombin (Sigma) or 50 ng/mL TNFα (R&D Systems). Medium 
(20µl) was collected from the lower chamber every 30 minutes for 2 hours. HRP 
content of the media samples was determined by measuring absorbance after the 
addition of 150µl of o-Phenylenediamine dihydrochloride buffer to each well of a 96-
well plate. 
 For VE-cadherin assays, PAECs were cultured in EBM-2 media (Lonza) with 
2% FBS for 24 hours with or without LPS, thrombin, TNFα and/or 10 ng/mL BMP9. 
Cells were then stained with FITC-conjugated rabbit polyclonal anti-VE-cadherin (cat 
#: LS-C40121, 1:100, Lifespan Biosciences, Seattle, WA). 
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Cell Proliferation assays  
For assessment of PAEC proliferation, cells were seeded at 30000 cells/well in 24-
well plates and left to adhere overnight. Cells were the washed with EBM2 containing 
0.1% FBS and then serum-restricted in EBM-2 containing 0.1% FBS. Cells were then 
treated with BMP9 (5ng/ml), VEGF165 (30ng/ml, both R&D Systems) or both ligands 
combined in EBM2 containing 2% FBS and treatments were replenished after 48 
hours. After 72 hours of ligand exposure, cells were trypsinised and counted using 
trypan blue exclusion to assess cell viability. 
 Proliferation of mouse PASMCs was determined as described previously44, in 
the presence of 1 ng/mL BMP9 or 10 ng/mL BMP4. 
 
Endothelial tube formation assays 
PAECs were cultured in a collagen and fibronectin gel matrix as previously 
described50. Briefly, cells were combined with the gel at a final concentration of 
1x106. The suspension was then pipetted into an angiogenesis µ-slide (Ibidi, 
Germany) in a volume of 10 µl/well. After 10 minutes at 37°C to allow 
polymerization, the gel was overlaid with 40µl of media (EBM-2, Lonza and 2% 
FBS), with or without 5 ng/ml BMP9 or 30 ng/mL VEGF165 (both R&D Systems) 
individually or combined. The 3-D cultures were left at 37°C for 24 hours and tube 
formation confirmed by brightfield microscopy. Images were collected and 
parameters measured and quantified using Image J software. In order to gain confocal 
images, gels were first fixed in 4% PFA, washed in PBS and incubated with 
Rhodamine labelled ULEX Europaeus Agglutinin1 (Vector Laboratories, Burlingame, 
CA) overnight at 4°C. After 3x 10 minute PBS washes, nuclear staining was carried 
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out using 10µl of VectorSHIELD mounting media with DAPI (Vector Laboratories) 
for 30 minutes. A final x3 wash in PBS was completed. 
 
Rodent models of PAH 
For all animal work, group sizes were determined using estimates of variance and 
minimum detectable differences between groups that were based on our past 
experience with rodent models of PAH. Animals were randomized using an assigned 
animal identification number, allowing investigators performing all cardiopulmonary 
phenotyping procedures and histological analyses to be blinded to animal genotype 
and treatment group. All animal work was carried out in accordance with the UK 
Animals (Scientific Procedures) Act 1986 and approved under Home Office Project 
Licence 80/2460. 
 
Mice 
All mice used in this work possessed a C57Bl/6 background.  Smad1+/– mice were 
obtained as a generous gift from the late Dr Anita Roberts33. For Bmpr2+/R899X mice, 
both male and female mice were studied. For Smad1+/– mice and Smad1+/–
/Bmpr2+/R899X compound heterozygotes, as well as littermate controls, only male mice 
were examined. 
 
Creation of Bmpr2+/R899X mice 
A gene targeting vector was created containing a 4.69kb 5’ homology arm and a 
1.84kb 3’ homology arm, separated by a loxP flanked neomycin expression cassette 
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(Supplementary Fig. 8). The 5’ homology arm, consisting of 4.69kb of intron 11, 
exon 12 and 30 bp of intron 12, was cloned into the pNTFLOX (kind gift of Dr. Jim 
Hughes) vector between the XhoI and NotI restriction sites using the following 
primers Fwd: 5’-GATC CTCGAG GTAAGGTCCT GAGGGGTTTG-3’; Rev: 
5’-GATCGCGGCCGCCAAAGGGTACTGCATAACCCCT-3’. The 1.84kb 3’ 
homology arm, consisting of intron 12 and exon 13, was cloned into PacI and KpnI 
sites using the following primers: Fwd: 5’-GATCTTAATTAAGGACAGTTAA 
ATAAAATAGA-3; Rev: 5’-GATCGGTACCTCACAGACAATTCATTCCTA-3’. 
The R899X substitution mutation was introduced into exon 12, 200bp upstream of the 
3’ end of the 5’ homology arm using the Stratagene Quickchange site-directed 
mutagenesis kit and the following primers: Fwd: 5’-
CCATTAGAAGGTGGCTGAACAAATTCCAAT-3’; Rev: 5’-
ATTGGAATTTGTTCAGCCACCTTCTAATGG-3’ following manufacturer’s 
instructions. For homologous recombination, the 5’ homology arm was truncated to 
1.72 kb and the resulting targeting vector was transfected into 129S3 mouse 
embryonic stem (ES) cells by electroporation. Neomycin resistant ES cell colonies 
were screened by polymerase chain reaction for homologous recombination. Correct 
targeting was confirmed by Southern blot using a neomycin-specific probe that 
allowed for the exclusion of random integration events of the targeting vector. 
Selected targeted ES cells were injected into C57Bl/6 blastocysts and chimeric mice 
were bred with C57Bl/6 females, resulting in heterozygous R899X offspring that were 
back-crossed to C57Bl/6 for >5 generations.  
 
Cardiopulmonary phenotyping, tissue collection and BMP9 treatment in mice 
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Three or six month-old mice were mice were anaesthetized with xylazine (4.6 mg/kg) 
and ketamine (7 mg/kg) and right and left ventricular pressures and volumes were 
recorded using a Millar PVR-1045 catheter (Millar Instruments, Houston, TX). Mice 
were then sacrificed and the hearts and lungs were harvested. Right ventricular 
hypertrophy was determined as a ratio of right ventricular to left ventricular and septal 
weight (RV/LV+S). The right lung was snap frozen in liquid nitrogen. The left lung 
was inflated with a 1:1 mixture of saline and OCT (Sakura, Zoeterwoude, 
Netherlands) and fixed with 4% paraformaldehyde in PBS prior to dehydration and 
paraffin embedding. A separate group of six month-old Bmpr2+/R899X mice and WT 
littermate controls were given daily i.p. injections of recombinant human BMP9 (75 
ng/mouse/day, gift from Pfizer) for 28 days prior to evaluation of cardiopulmonary 
haemodynamics. 
 
Monocrotaline rat model 
Male Sprague Dawley rats (~200 to 250 grams, Charles River, Margate, UK) were 
randomized into three groups.  Control rats were given intraperitoneal injections of 
sterile water as a vehicle control. Rats on the prevention protocol were given 60 
mg/kg of MCT (Sigma, St. Louis, MO) by i.p. injection and treated with daily i.p. 
injections of recombinant human BMP9 (600 ng/day) or vehicle control from day 0 
until sacrifice on days 2, 5 or 21. Rats on the reversal protocol were given 40 mg/kg 
of MCT, allowed to develop PAH from days 0 to 21, and treated with BMP9 (600 
ng/day) or vehicle control from day 21 to sacrifice on day 35. At the time of sacrifice, 
animals were anaesthetized with xylazine (4.6 mg/kg) and ketamine (7 mg/kg) and 
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right and left ventricular function were assessed using a Millar SPR-869 pressure-
volume catheter. Tissue harvesting was carried out as described above for mice.  
 
SU-5416-chronic hypoxia rat model  
Male Sprague Dawley rats (~150 to 200 grams, Charles River) were given a single 
intraperitoneal injection of SU-5416 (20 mg/kg, Tocris, Bristol, UK) in vehicle (0.5% 
carboxyl methylcellulose sodium, 0.4% polysorbate 80, 0.9% Benzyl alcohol, all 
Sigma), placed immediately into a 10% O2 chamber and maintained in hypoxia for 3 
weeks, followed by 5 weeks in a normoxic environment to develop pulmonary 
hypertension.  At the 8-week time point, rats were randomized into 3 groups.  One 
group was assessed for cardiopulmonary function and sacrificed as described for the 
monocrotaline model above, while the other two groups received 3 weeks of daily i.p. 
injections with 600 ng/day BMP9 or saline vehicle as a control prior to 
cardiopulmonary phenotyping and sacrifice as described above.  
 
SU-5416-chronic hypoxia mouse model 
Six month-old male C57/BL6 mice (~30-35 g, Charles River) were given weekly 
subcutaneous (infrascapular) injections of SU-5416 (20 mg/kg) in vehicle (0.5% 
carboxyl methylcellulose sodium, 0.4% polysorbate 80, 0.9% Benzyl alcohol, all 
Sigma), placed immediately into a 10% O2 chamber and maintained in hypoxia for 3 
weeks.  During this treatment period, mice were randomized into 4 groups.  One 
group received vehicle alone without hypoxia or SU-5416, while another group 
received BMP9 (75 ng/day in saline i.p.) daily injections without hypoxia or SU-
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5416.  Among mice receiving hypoxia and SU-5416, one group received vehicle 
while the remainder received BMP9 daily injections.  In addition, a cohort of mice 
maintained in normoxia received daily intramuscular injections of BMP9 (75 ng/day) 
into the right hamstring muscle.  Mice were assessed for cardiopulmonary function 
and sacrificed as described for the genetic mouse model above, and then subjected to 
conventional x-ray (Carestream in vivo imager) and micro-CT analysis (ScanCo 
µCT40). 
 
Assessment of Nonsense Mediated Decay  
PASMCs were seeded in 6cm plates and grown to approximately 1 × 103 cells/plate. 
Puromycin (Sigma) was added to 100 μg/ml for 20 h prior to harvesting. Parallel 
plates with and without puromycin were harvested for RNA analysis and a third plate 
for DNA.  DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, 
CA) and RNA using the miRNeasy Mini Kit with on-column DNase treatment.  First-
strand cDNA synthesis was performed using Superscript III (Life Technologies, 
Carlsbad, CA) with random hexamer priming. The region of BMPR2 exon 12 
containing the R899X mutation was analyzed by dideoxy sequencing of PCR products 
(conditions and primers available on request).  To ensure specificity for the target 
nucleic acid, DNA was amplified using an intronic reverse primer and RNA was 
amplified with primers spanning intron 12. 
 
Immunohistochemistry 
For assessment of pulmonary arteriolar muscularization, sections of fixed rat lung 
tissue (5μm) were labeled with monoclonal mouse-anti-mouse/rat/human smooth 
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muscle α-actin (clone 1A4, Dako, Glostrup, Denmark), followed by polyclonal goat 
anti-mouse HRP. For mouse lung tissue, Dako ARKTM was used in accordance with 
the manufacturer’s instructions. Briefly, the primary antibody was labeled by a 
modified biotinylated anti-mouse immunoblobulin prior to application to the 
specimen. The primary antibody and Biotinylation Reagent were mixed in solution, 
resulting in binding of biotinylated secondary antibody to the primary antibody. The 
Blocking Reagent, containing normal mouse serum, was then added to the mixture to 
bind residual Biotinylation Reagent not bound to the primary antibody, minimizing 
potential interaction with immunoglobulin endogenous in the specimen. The biotin-
labeled primary antibody was then applied to the specimen followed by incubation 
with streptavidin-peoxidase and reaction with diaminobenzidine (DAB)/hydrogen 
peroxide as substrate-chromogen.   
Assessment of pulmonary arteriolar muscularization involved the 
identification of alveolar ducts and the subsequent categorization of the 
accompanying intra-acinar artery as non, partially or fully muscularized. A minimum 
of 20 vessels with diameters ranging from 25 to 75 μm were counted from non-serial 
lung sections and categorized as either fully, partially or non-muscularized. Statistical 
significance was assessed by comparing the percentage of fully muscularized vessels 
between groups. Assesment of muscularization was performed blinded. 
Alternatively, immunofluorescent assessment of mouse lung sections was 
performed using rabbit anti-vWF (Dako A0082) at 1:200 in 5% goat serum, followed 
by Alexa-488 conjugated anti-rabbit secondary antibody (Molecular Probes), as well 
as monoclonal anti-SM alpha actin (Sigma) at 1:100 in 5% goat serum followed by 
Alexa-555 conjugated anti-mouse secondary antibody (Molecular Probes).  
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For assessment of neointima formation, rat lung sections were also stained 
with Elastic Van Gieson (EVG) stain and examined by light microscopy. 
Quantification of endothelial cell apoptosis in rat lungs was performed by staining 
fixed rat lung sections with a rabbit monoclonal antibody towards cleaved caspase-3 
(clone 5A1E, Cell Signaling Technology) or a rabbit polyclonal antibody towards 
vonWillebrand factor (catalogue # ab9378, Abcam, Cambridge, UK) and labeled 
using immunoperoxidase (Vectastain Elite, Vector Laboratories) and 3,3’-DAB to 
create a brown coloured reaction product. Cleaved caspase-3 positive cells on the 
luminal surface of 25 to 75 μm pulmonary vessels were vascular were quantified and 
normalized to total tissue area using Image J. 
Ex-vivo stimulation of rat pulmonary artery and subsequent staining for 
phosphorylated Smad1/5 was performed as described previously for rat aortas51. 
Isolated pulmonary arteries were stimulated ex vivo for 1 hour with 5 ng/mL BMP9 
prior to fixation and paraffin embedding. 
 
Evans Blue Dye Permeability Assay 
Permeability of Evans blue dye in response to LPS challenge was determined as 
described previously52. Briefly, animals were injected i.p. with 2mg/kg LPS (Sigma 
Aldrich) or vehicle and either 36.79 ng/25g recombinant human BMP9 or vehicle 22 
hours prior to the i.p. injection of 6 mL/kg of 1% Evans blue dye in PBS with 4% 
bovine serum albumin (equivalent to 20 mg/kg Evans blue).  Two hours after the 
injection of Evans blue, animals were sacrificed, the left atrium was clipped and the 
lung vasculature was flushed with 10mL of PBS per mouse via the right ventricle to 
remove intravascular EB. Flushed lungs were photographed and right and left lungs 
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were separately weighted and snap frozen in liquid nitrogen. Right lungs were 
homogenized in formamide (1ml/100mg lung), and incubated for 24 hr at 37ºC. 
Homogenates were clarified by centrifugation at 12,000 g for 20 min and the 
absorbance of 200µl of clarified supernatant was measured at 620nm in a 96-well 
plate.  
 
Statistical Methods 
Student’s t-tests were used for comparisons between two groups. Multiple 
comparisons were assessed by one-way ANOVA, followed by the appropriate post-
hoc test for significance, as specified in the figure legends. Equivalence of variance 
between experimental groups was confirmed using an F-test for comparisons between 
two groups and a Brown-Forsythe test in conjunction with ANOVA, when applicable. 
Normal distribution was assumed for all statistical analyses and confirmed when 
group sizes allowed for testing of normality.  All statistical tests used two-sided tests 
of significance. All data are reported as mean +/– SEM. 
 
Methods-only References  
 
42. Geti, I., et al. A Practical and Efficient Cellular Substrate for the Generation of 
Induced Pluripotent Stem Cells from Adults: Blood-Derived Endothelial 
Progenitor Cells. Stem Cells Translational Medicine 1, 855-865 (2012). 
43. Allport, J.R., et al. Neutrophils from MMP-9- or neutrophil elastase-deficient 
mice show no defect in transendothelial migration under flow in vitro. J 
Leukoc Biol 71, 821-828 (2002). 
44. Yang, X., et al. Dysfunctional Smad signaling contributes to abnormal smooth 
muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 
96, 1053-1063 (2005). 
 44
45. Smyth, G.K. Limma: linear models for microarray data. in Bioinformatics and 
Computational Biology Solutions using R and Bioconductor (eds. Gentleman, 
R., Carey, V., Dudoit, S., Irizarry, R. & W., H.) 397-420 (Springer, New 
York, 2005). 
46. Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D. & Woolf, P.J. 
GAGE: generally applicable gene set enrichment for pathway analysis. BMC 
bioinformatics 10, 161 (2009). 
47. Tarca, A.L., et al. A Novel Signaling Pathway Impact Analysis (SPIA). 
Bioinformatics (2008). 
48. Luo, W. & Brouwer, C. Pathview: an R/Bioconductor package for pathway-
based data integration and visualization. Bioinformatics 29, 1830-1831 (2013). 
49. Harrington, E.O., et al. Role of protein kinase C isoforms in rat epididymal 
microvascular endothelial barrier function. Am J Respir Cell Mol Biol 28, 626-
636 (2003). 
50. Waters, J.P., et al. In vitro self-assembly of human pericyte-supported 
endothelial microvessels in three-dimensional coculture: a simple model for 
interrogating endothelial-pericyte interactions. J Vasc Res 50, 324-331 (2013). 
51. Bidart, M., et al. BMP9 is produced by hepatocytes and circulates mainly in 
an active mature form complexed to its prodomain. Cellular and molecular 
life sciences : CMLS 69, 313-324 (2012). 
52. Moitra, J., Sammani, S. & Garcia, J.G. Re-evaluation of Evans Blue dye as a 
marker of albumin clearance in murine models of acute lung injury. 
Translational research : the journal of laboratory and clinical medicine 150, 
253-265 (2007). 
 
 
 






